New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders. The first histone deacetylase inhibitor, vorinostat, has been lice...

Descripción completa

Detalles Bibliográficos
Autores principales: Cang, Shundong, Ma, Yuehua, Liu, Delong
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695818/
https://www.ncbi.nlm.nih.gov/pubmed/19486511
http://dx.doi.org/10.1186/1756-8722-2-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695818/
https://www.ncbi.nlm.nih.gov/pubmed/19486511
http://dx.doi.org/10.1186/1756-8722-2-22

Ejemplares similares